On November 7, 2024, Doximity, Inc., a leading digital platform for U.S. medical professionals, reported its financial results for the fiscal quarter ending September 30, 2024. The company announced a 20% increase in revenue to $136.8 million compared to the same period last year, and a significant growth in net income by 44%, reaching $44.2 million. Adjusted EBITDA also saw a substantial rise of 41% year-over-year, amounting to $76.1 million. Doximity's CEO, Jeff Tangney, highlighted the record use of the company's clinical workflow tools, with over 600,000 unique active prescribers during the quarter. The company's financial outlook for the fiscal third quarter ending December 31, 2024, projects revenue between $152 million and $153 million, and adjusted EBITDA between $83 million and $84 million. For the fiscal year ending March 31, 2025, Doximity updated its guidance to a revenue range of $535 million to $540 million and adjusted EBITDA between $274 million and $279 million. The company's strong performance is attributed to its mission of providing digital tools that enhance medical professionals' productivity and patient care.

On November 7, 2024, Doximity, Inc., a leading digital platform for U.S. medical professionals, reported its financial results for the fiscal quarter ending September 30, 2024. The company announced a 20% increase in revenue to $136.8 million compared to the same period last year, and a significant growth in net income by 44%, reaching $44.2 million. Adjusted EBITDA also saw a substantial rise of 41% year-over-year, amounting to $76.1 million. Doximity's CEO, Jeff Tangney, highlighted the record use of the company's clinical workflow tools, with over 600,000 unique active prescribers during the quarter. The company's financial outlook for the fiscal third quarter ending December 31, 2024, projects revenue between $152 million and $153 million, and adjusted EBITDA between $83 million and $84 million. For the fiscal year ending March 31, 2025, Doximity updated its guidance to a revenue range of $535 million to $540 million and adjusted EBITDA between $274 million and $279 million. The company's strong performance is attributed to its mission of providing digital tools that enhance medical professionals' productivity and patient care.